Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot may prevent dangerous clots after knee surgery

NCT ID NCT06454630

Prevention Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called REGN7508 in 179 adults having knee replacement surgery. The goal was to see if it could prevent blood clots in the legs or lungs better than standard care. Researchers also monitored side effects and how the drug moved through the body.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

179 people

The number who actually took part.

Started

Jun 2024

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. Undergoing a primary elective unilateral TKA 2. Has a body weight ≤130 kg at screening visit 3. Is judged by the investigator to be in good health based on medical history, physical examination, vital sign measurements, and electrocardiograms (ECG's) performed at screening and/or prior to administration of initial dose of study drug as described in the protocol 4. Is in good health based on laboratory safety testing obtained during the screening period as described in the protocol Key Exclusion Criteria: 1. History of bleeding in the past 6 months prior to dosing requiring hospitalization or transfusion; history of intracranial or intraocular bleeding, excessive operative or post-operative bleeding, and traumatic spinal or epidural anesthesia; history of bleeding diathesis 2. History of thromboembolic disease or thrombophilia 3. History of major surgery, including brain, spinal, or ocular, within approximately the past 6 months 4. History of major trauma within approximately the past 6 months prior to dosing 5. Hospitalized (\>24 hours) for any reason within 30 days of the screening visit 6. Has an estimated glomerular filtration rate (GFR) of \<45 mL/min/1.73m\^2 at the screening visit using one of the following formulas: the Modification of Diet in Renal Disease (MDRD) equation, the Chronic Kidney Disease Epidemiology Collaboration equation, or equivalent equation Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Venous thromboembolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Venous thromboembolism

Contacts and locations

Locations

  • Budai Irgalmasrendi Korhaz

    Budapest, 1027, Hungary

  • Clinic of Orthopaedics and Paediatric Orthopaedics

    Lodz, Łódź Voivodeship, 92-213, Poland

  • Hospital of Traumatology and Orthopaedics

    Riga, LV-1005, Latvia

  • Klaipeda University Hospital

    Klaipėda, LT-92288, Lithuania

  • Liepaja Regional Hospital

    Liepāja, LV-3414, Latvia

  • Lietuvos sveikatos mokslu universiteto ligonine Kauno klinik

    Kaunas, Kaunas County, LT-50161, Lithuania

  • Lithuanian University of Health Sciences Kaunas Hospital

    Kaunas, LT-48142, Lithuania

  • Multi-profile Hospital for Active Treatment Hearth and Brain EAD

    Pleven, 5800, Bulgaria

  • Multiprofile Hospital For Active Treatment Park Hospital Ltd.

    Plovdiv, 4002, Bulgaria

  • Orto Klinika

    Riga, LV-1005, Latvia

  • Riga's 2nd Hospital

    Riga, LV-1004, Latvia

  • Specjalistyczny Szpital im. E. Szczeklika w Tarnowie

    Tarnów, Lesser Poland Voivodeship, 33-100, Poland

  • Szolnoki MAV Hospital

    Szolnok, 5000, Hungary

  • Vidzemes Hospital

    Valmiera, Valmieras Aprinkis, LV-4201, Latvia

More trials for these conditions

Other studies related to the condition(s) this trial covers.